Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://www.thejh.org

Case Report

Volume 11, Number 2, April 2022, pages 77-80

COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma

Figures

Figure 1.
Figure 1. Monocyte CD169 expression during the overt COVID-19 infection and after the clinical recovery obtained with hyperimmune plasma. The reduced CD169 monocyte/lymphocyte ratio at discharge correlates with the viral clearance. (a) Dot plot SSC/CD64. Monocytes (Mono, blue) and lymphocytes (Lympho, green) are identified on the basis of their respective intensity of expression of CD64. (b) The green histogram represents the CD169 intensity on lymphocytes (negative control) and the blue histogram the CD169 intensity on monocytes at presentation with an intensity ratio of 72.7. (c) After hyperimmune plasma treatment, a significant decrease of the ratio was found, indicating viral clearance (5.3). COVID-19: coronavirus disease 2019; SSC: side scatter.
Figure 2.
Figure 2. Clinical course. The patient received 12 courses of rituximab (RTX) and remained B-cell-depleted for months, being unable to mount an antibody response against SARS-CoV-2. She remained persistently positive for nasopharyngeal molecular swabs and with pulmonary involvement. Clinical recovery and negativization of molecular swab occurred after the administration of two units of hyperimmune convalescent plasma. SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.